Belfius

Belfius is THE Bank for Life Sciences Companies in Belgium.

Belfius and Europe’s leading independent equity broker, Kepler Cheuvreux, have entered into a strategic partnership with strong local presence in Belgium since 2017. Together, Belfius and Kepler Cheuvreux propose a top-ranked offering in Equity Capital Markets (ECM transactions), equity research, institutional sales and brokerage. Under this innovative ECM partnership, Belfius has responsibility for origination and structuring services for equity capital market transactions in Belgium whereas Kepler Cheuvreux provide equity research, brokerage and institutional sales.

In the Life Sciences area specifically, Belfius can leverage the unrivaled equity coverage of Kepler Cheuvreux with close to 100 life science companies (pharmaceutical, medtech & biotech) across Europe covered by a team of 6 highly skilled analysts. Recently, Belfius has successfully helped Life Sciences companies such as ONWARD Medical (IPO), Biotalys (IPO), Nyxoah(IPO), Fagron NV, Bone Therapeutics, Sequana Medical, Biocartis and Mithra Pharmaceuticals in raising new capital.

Belfius is a very successful integrated bank-insurer anchored in all segments of the Belgian economy; with an unparalleled leadership in the public sector of more than 150 years. Over the recent years, Belfius has gained significant market share to become a reference bank for the SME and Corporates in Belgium; offering a full product and solutions suite. For further details, please go to: www.belfius.com

Kepler Cheuvreux is a leading independent European financial services company specialised in advisory services and intermediation. Kepler Cheuvreux employs +130 equity research analysts who target to research 1,000 European companies by the end of 2019. Kepler Cheuvreux has the largest equity research footprint in Continental Europe. For further details, please go to: www.keplercheuvreux.com